696 related articles for article (PubMed ID: 25745066)
21. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Ferrari de Andrade L; Tay RE; Pan D; Luoma AM; Ito Y; Badrinath S; Tsoucas D; Franz B; May KF; Harvey CJ; Kobold S; Pyrdol JW; Yoon C; Yuan GC; Hodi FS; Dranoff G; Wucherpfennig KW
Science; 2018 Mar; 359(6383):1537-1542. PubMed ID: 29599246
[TBL] [Abstract][Full Text] [Related]
22. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
23. The innate immune response to tumors and its role in the induction of T-cell immunity.
Diefenbach A; Raulet DH
Immunol Rev; 2002 Oct; 188():9-21. PubMed ID: 12445277
[TBL] [Abstract][Full Text] [Related]
24. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
25. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
26. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
27. Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress.
Nice TJ; Coscoy L; Raulet DH
J Exp Med; 2009 Feb; 206(2):287-98. PubMed ID: 19171762
[TBL] [Abstract][Full Text] [Related]
28. Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation.
Kotturi HS; Li J; Branham-O'Connor M; Stickel SL; Yu X; Wagner TE; Wei Y
Gene Ther; 2008 Oct; 15(19):1302-10. PubMed ID: 18463688
[TBL] [Abstract][Full Text] [Related]
29. NKG2D and Its Ligands: "One for All, All for One".
Zingoni A; Molfetta R; Fionda C; Soriani A; Paolini R; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():476. PubMed ID: 29662484
[TBL] [Abstract][Full Text] [Related]
30. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
31. A dual function of NKG2D ligands in NK-cell activation.
Cheney EE; Wise EL; Bui JD; Schreiber RD; Carayannopoulos LN; Spitzer D; Zafirova B; Polic B; Shaw AS; Markiewicz MA
Eur J Immunol; 2012 Sep; 42(9):2452-8. PubMed ID: 22740149
[TBL] [Abstract][Full Text] [Related]
32. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
[TBL] [Abstract][Full Text] [Related]
33. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection.
Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A
J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
36. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
37. NKG2D signaling in cancer immunosurveillance.
López-Soto A; Huergo-Zapico L; Acebes-Huerta A; Villa-Alvarez M; Gonzalez S
Int J Cancer; 2015 Apr; 136(8):1741-50. PubMed ID: 24615398
[TBL] [Abstract][Full Text] [Related]
38. NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis.
Legroux L; Moratalla AC; Laurent C; Deblois G; Verstraeten SL; Arbour N
Front Immunol; 2019; 10():154. PubMed ID: 30787931
[TBL] [Abstract][Full Text] [Related]
39. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
40. Ras activation induces expression of Raet1 family NK receptor ligands.
Liu XV; Ho SS; Tan JJ; Kamran N; Gasser S
J Immunol; 2012 Aug; 189(4):1826-34. PubMed ID: 22798674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
